<DOC>
	<DOCNO>NCT00329160</DOCNO>
	<brief_summary>The primary objective study evaluate 76 week treatment rosuvastatin calcium 2.5-20 mg result progression coronary artery atherosclerotic volume measure intravascular ultrasonography ( IVUS ) image hypercholesterolaemic subject coronary heart disease ( CHD ) .</brief_summary>
	<brief_title>Rosuvastatin Long-term Treatment Hypercholesterolaemic Subjects With Coronary Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed write informed consent , 20 75 year old , Plan undergo coronary angiography ( CAG ) Percutaneous coronary intervention ( PCI ) LDLC ≥ 140 mg/dL ( untreated patient ) LDLC ≥ 100 mg/dL ( treated patient ) Acute myocardial infarction within 72 hour onset , Heart failure New York Heart Association ( NYHA ) Class III , Serious arrhythmia , Being treat LDLapheresis History serious reaction hypersensitivity HMGCoA reductase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>